Skip to main content

Generics

  • Survey: Latinos see diabetes as biggest health concern for their families

    BOSTON — A new NPR/Robert Wood Johnson Foundation/Harvard School of Public Health poll released Tuesday found that Latinos in America see diabetes as the biggest health problem for their own families.

    Nearly 1-in-5 (19%) Latinos said diabetes is the biggest health problem facing their families. The next most cited problem, cancer, is mentioned by just 1-in-20 Latinos (5%). Diabetes was the biggest health problem reported by both immigrant (16%) and non-immigrant Latinos (22%).

  • FDA launches advisory committee membership nomination portal

    SILVER SPRING, Md. — The Food and Drug Administration on Wednesday launched the advisory committee membership nomination portal, an online, interactive system that allows interested individuals to submit nominations for membership to any of the agency’s 33 advisory committees.  

  • Mission Pharmacal publishes 'ABCs of Medical Management of Stones' as an Apple app

    SAN ANTONIO — Mission Pharmacal Co. on Tuesday announced its “ABCs of Medical Management of Stones,” a step-by-step approach to the diagnosis and treatment of nephrolithiasis, or kidney stones, is now available as a mobile application for Apple devices.

  • Actavis Pharma to sell seven Western European operations to Aurobindo Pharma

    DUBLIN — Actavis Pharma recently announced that it intends to enter into an agreement for Aurobindo Pharma to acquire Actavis' generics commercial operations in seven markets in Western Europe. The transaction is conditional on certain antitrust approvals and completion of employee consultation processes. 

  • Par to acquire JHP

    WOODCLIFF LAKE, N.J. — Par Pharmaceuticals Cos. on Tuesday announced that it entered into an agreement to acquire JHP Group Holdings, parent company of JHP Pharmaceuticals.

    JHP is a specialty pharmaceutical company that develops, manufactures and markets branded and generic sterile injectable products. It currently markets a portfolio of 14 specialty injectable products, such as Aplisol and Adrenalin.

  • Teva Pharmaceutical acquires NuPathe and migraine patch Zecuity

    JERUSALEM — Teva Pharmaceutical on Tuesday announced that it has entered into a definitive agreement under which Teva will acquire NuPathe for $3.65 per share in cash, or approximately $144 million. In addition to the upfront cash payment, NuPathe shareholders will receive rights to receive additional cash payments of up to $3.15 per share if specified net sales of NuPathe's migraine treatment, Zecuity, are achieved over time.

  • Actavis' Lo Loestrin Fe patent upheld

    DUBLIN — Actavis last week confirmed that the U.S. District Court for the District of New Jersey found United States Patent No. 7,704,984 (the '984 Patent) to be valid and infringed by Lupin Pharmaceuticals and Amneal Pharmaceuticals Abbreviated New Drug Applications (ANDAs) for generic versions of Actavis' Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets).  

    Lo Loestrin Fe is a prescription birth control pill used for the prevention of pregnancy.

  • Greenstone launches authorized generic of Pfizer's Rapamune

    PEAPACK, N.J. — Greenstone, a U.S.-based generic pharmaceutical subsidiary of Pfizer, on Tuesday announced the introduction of Sirolimus to its generic pharmaceutical product line. The product is offered in dosage strengths of 0.5mg x 100. 

    Greenstone’s Sirolimus product is the authorized generic of, and equivalent to, Pfizer's Rapamune (sirolimus). 

X
This ad will auto-close in 10 seconds